Abstract
Get full access to this article
View all access options for this article.
References
1.Paragon Bioservices . Gene therapy & rare diseases . 2019 . https://paragonbioservices.com/therapeutic-areas/gene-therapy (last accessed May 16 , 2019
2.Catalent . Catalent To Acquire Gene Therapy Leader Paragon Bioservices, Inc . For $1.2 Billion . 2019 . www.catalent.com/index.php/news-events/news/Catalent-to-acquire-gene-therapy-leader-Paragon-Bioservices-Inc.-for-1.2-billion (last accessed May 16 , 2019
3.Novartis . New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) type 1 . 2019 . www.novartis.com/news/media-releases/avexis-data-reinforce-effectiveness-zolgensma-treating-spinal-muscular-atrophy-sma-type-1 (last accessed May 17 , 2019
4.Reuters . Novartis confident of Zolgensma supply, calls $2 million price ‘speculation’ . 2019 . www.reuters.com/article/us-novartis-sma/novartis-confident-of-zolgensma-supply-calls-2-million-price-speculation-idUSKCN1SE23O (last accessed May 17 , 2019
5.Reuters . Novartis confident of Zolgensma supply, calls $2 million price ‘speculation’ . 2019 . www.reuters.com/article/us-novartis-sma/novartis-confident-of-zolgensma-supply-calls-2-million-price-speculation-idUSKCN1SE23O (last accessed May 17 , 2019
6.
Beasley
D
,
Miller
J
Exclusive: Novartis pitches discounts on pricey gene therapy for deadly muscle disorder . Reuters May 10, 2019 . www.reuters.com/article/us-novartis-sma/novartis-confident-of-zolgensma-supply-calls-2-million-price-speculation-idUSKCN1SE23O (last accessed May 17 , 2019
7.uniQure . uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B . 2019 . https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3608549&lang=en-GB&companycode=nl-qure&v=(last accessed May 17 , 2019
8.Verve Therapeutics . Verve therapeutics founded to protect against heart disease launches with $58.5 million in series A funding led by GV . 2019 . www.businesswire.com/news/home/20190507005300/en/Verve-Therapeutics-Founded-Protect-Heart-Disease-Launches (last accessed May 16 , 2019
9.Audentes Therapeutics . Audentes therapeutics announces launch of new state-of-the-art internal cGMP plasmid manufacturing facility . 2019 . https://audentestx.gcs-web.com/news-releases/news-release-details/audentes-therapeutics-announces-launch-new-state-art-internal (last accessed May 16 , 2019
10.Emendo Biotherapeutics . Emendo Biotherapeutics enters into licensing option agreement with Takeda for its OMNI nuclease program . 2019 . www.prnewswire.com/news-releases/emendo-biotherapeutics-enters-into-licensing-option-agreement-with-takeda-for-its-omni-nuclease-program-300836189.html (last accessed May 16 , 2019